MET amplification has been proven to lead to acquired level of resistance to the EGFR tyrosine kinase inhibitor (TKI) gefitinib in non-small-cell lung cancers (NSCLC) harboring activating mutations (27, 31)
MET amplification has been proven to lead to acquired level of resistance to the EGFR tyrosine kinase inhibitor (TKI) gefitinib […]